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Abstract
Background: Although morbidity and mortality from coronary heart disease (CHD) are high, only
a minority of acute coronary syndrome (ACS) survivors accesses an effective secondary prevention
program. We aim to determine whether the previously proven CHOICE program can be
replicated at multiple sites and whether ongoing reinforcement further improves risk factor
modification.
Methods/design: Participants eligible for but not accessing standard cardiac rehabilitation will be
randomly allocated to either a previously tested 3-month CHOICE program or a 30-month
CHOICE program (CHOICE-plus). Both groups will participate in individualised risk factor
modules of differing duration that involve choice, goal setting and telephone follow-up for three
months. CHOICE-plus  will also receive additional face-to-face and telephone reinforcement
between three and 30 months. At one site we will recruit a randomised control group, receiving
conventional care. Primary outcomes are lipid levels, blood pressure, physical activity levels and
smoking rates. Secondary outcomes include readmission rates, death, the number of risk factors,
other modifiable risk factors, quality of life and process evaluation measures over three years.
Discussion: We present the rationale and design of a multi-centre, replication study testing a
modular approach for the secondary prevention of CHD following an ACS.
Trial Registration: [Clinical Trial Registration Number, ACTRN12608000182392]
Background
Coronary heart disease (CHD) is a leading cause of death
and disability in Australia and costs associated with treat-
ment are high [1]. Survivors of an acute coronary syn-
drome (ACS) have a 5% risk of a recurrence, some six
times greater than that of the general population [2] and
are advised to participate in a secondary prevention pro-
gram [3,4]. Such programs incorporate lifestyle advice
and pharmacotherapy to reduce recurrent cardiovascular
events, improve survival and enhance quality of life [4].
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The population is aging and thus the prevalence of CHD
is expected to increase [5]. Similarly, the number of peo-
ple surviving an ACS is rising largely due to improvements
in acute treatment [6,7]. Because of these increases, the
need to provide effective secondary prevention programs
is escalating. In addition, three recent large studies con-
cluded that effective risk factor reduction has reduced
mortality from CVD by around 50% [6-8].
Cardiac rehabilitation (CR) programs aim to reduce coro-
nary risk factors, facilitate patients return to normal activ-
ities and reduce their overall cardiovascular risk, in
addition to stabilising, slowing or even reversing the
underlying atherosclerotic process [9,10]. However,
despite the potential benefits of CR, only a minority of
people with CHD (10–30%) participate in existing pro-
grams [11,12]. Reasons for poor attendance include geo-
graphical location, being of lower socio-economic group
and low referral rates for the elderly and women [13]. In
addition, even in those who attend, long-term compliance
with exercise-only CR regimens is only around 50% [13].
Disconcertingly, the majority of ACS survivors, who are at
high risk of a future cardiac event, do not access a formal
secondary prevention program resulting in a significant
evidence-practice gap. In a single-centre study, it was dem-
onstrated that ACS survivors not accessing CR had higher
levels of individual risk factors including elevated total
cholesterol (TC), low density lipoprotein (LDL) choles-
terol, current smokers, hypertension, overweight, are less
physically active, and were therefore at much greater over-
all risk than CR attendees [14]. Non-CR attendees also
had much poorer knowledge of their risk factors, where
75% were unable to state even one of their own risk fac-
tors [14].
CHD is a chronic condition, and changes to lifestyle and
adherence to pharmacotherapy have to be life-long. Stud-
ies have tried to address this evidence-practice gap
through education and counselling of risk factor targets
and medications with success [15,16]. Using a simple,
innovative patient-centred modular approach to second-
ary prevention in a randomised controlled trial (n = 208)
[17,18], it was found that the Choice of Health Options In
prevention of Cardiovascular Events (CHOICE) program
was readily acceptable to ACS survivors who did not
access standard CR. It was also found that the intervention
group significantly reduced individual cardiovascular risk
factors and overall risk, and had significantly better risk
factor knowledge at both three and 12 month follow-up
compared to baseline and compared to having conven-
tional care with their usual general practitioner and/or
cardiologist [19-21]. Therefore, it was demonstrated at a
single hospital site that the evidence-practice gap could be
reduced for up to 12 months.
The original CHOICE trial provided a successful second-
ary prevention option for patients not accessing CR at a
single site but it is now imperative to determine if the
findings are replicable at multiple sites, delivered by mul-
tiple health professionals and to examine the processes
which influence the implementation of a successful trial
into a "real-life" setting [22]. The aim of this study is to
establish if the CHOICE program can be replicated at mul-
tiple hospitals over three years. We also aim to investigate
whether 30 months of telephone support is more benefi-
cial than three months.
Methods/design
Design
This replication study, with a single site randomised con-
trol group, with three year follow up will be conducted at
four tertiary referral hospitals in Sydney, Australia (figure
1) and is registered on the Australian and New Zealand
Clinical Trials Registry (ACTRN12608000182392). Across
all four sites patients not accessing standard CR will be
randomly allocated to either a group participating in a
three month CHOICE program or a 30 month CHOICE
program (CHOICE-plus). At one site, patients not access-
ing CR will be allocated to one of three groups; the previ-
ously described intervention groups or a randomised
control group participating in conventional care (figure
1), which will allow investigation of the effect of an addi-
tional nutrition module and a more tailored approach to
depression.
Blinded assessments will be conducted at baseline and 36
months during a face-to-face interview. At 12 months,
assessments will be completed by the intervention nurse
and to ensure validity, a sample of 20 patients will have
their measurements repeated by an independent assessor,
blinded to group allocation. At follow-up assessments,
additional data will be collected, including details of any
unplanned hospital admissions, medications and doses
and details of visits to the family physician, cardiologist
and attendance at any community program pertaining to
their heart health. Ethical approval for this study has been
granted by Sydney South West Area Health Services and
will be sought from the University of Sydney Human
Research Ethics Committees. Written and informed con-
sent will be obtained from all study participants prior to
commencement.
Study population
The hospital CR coordinators who review the Cardiology
Department admission summaries daily will identify
potential participants. Inclusion criteria for the study are;
diagnosis of ACS up to eight weeks prior to recruitment;
refusal of the initial invitation to participate in standard
CR; failure to attend initial CR assessment. Exclusion cri-
teria are: clinical diagnosis of uncompensated, severe car-BMC Cardiovascular Disorders 2008, 8:25 http://www.biomedcentral.com/1471-2261/8/25
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diac failure (Class IV); uncontrolled arrhythmia or angina;
severe or symptomatic aortic stenosis; persistent hypoten-
sion (SBP < 90 mmHg); clinical diagnosis of a severe coex-
isting medical condition that would prevent participation
(e.g., dementia, a terminal illness, severe rheumatoid
arthritis); or insufficient English to provide written
informed consent. The primary criterion for eligibility for
recruitment will be declining an offer to access existing
CR. This will also include patients who are not offered CR
while an inpatient but decline a subsequent offer to attend
the CR program.
Group allocation
Patients meeting the inclusion and exclusion criteria will
be approached by the hospital CR coordinator or research
assistant, during their inpatient stay where possible, or via
letter or telephone soon after hospital discharge. Those
who volunteer will have a baseline assessment and an ini-
tial face-to-face module selection and goal-setting session
(approximately one hour in duration). This session will
take place during the inpatient stay or in outpatient clini-
cal consulting rooms, or, if necessary, at the participant's
home, within one month of discharge. After baseline
Design of the CHOICE study Figure 1
Design of the CHOICE study. ACS: acute coronary syndrome. CHOICE: Choice of Health Options In prevention of Car-
diovascular Events.
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measurements are completed, at three sites, participants
will be randomly allocated to one of the two groups
(CHOICE or CHOICE-plus). At the remaining site partici-
pants will be randomly allocated to one of three groups
(control, CHOICE or CHOICE-plus). Randomisation will
be undertaken by an independent researcher (at the Uni-
versity of Sydney) with a computer-generated random
allocation sequence and will be concealed from the health
professional obtaining consent and conducting baseline
assessment.
Interventions
Participants randomly allocated to the control group at
the single site will participate in ongoing conventional
care, aimed at managing their cardiovascular health as
directed by their family physician, ideally in consultation
with their cardiologist. The control group will be advised
to seek the advice of their family physician and cardiolo-
gist but will receive no additional intervention as a result
of participation in the study.
Participants in both the CHOICE and CHOICE-plus
groups will take part in a three-month patient-centred
modular secondary prevention program. The CHOICE-
plus group will also be offered additional face-to-face rein-
forcement at 12 and additional telephone reinforcement
at six, 18 and 30 months.
As described elsewhere, the CHOICE intervention
includes a one-hour initial consultation and follow-up
phone calls over three months [20]. The program is
designed to have an individualised, structured, case-man-
agement approach and is overseen by treating physicians.
The development and implementation of the CHOICE
program can be divided into four stages (figure 2). Stage
one involves the development of modules and tailoring of
leaflets to access recommended local services [21]. Stage
two is a face-to-face risk factor assessment, lasting approx-
imately one hour in which the patient is assisted to gener-
ate a list of their own relevant risk factors. In stage three,
patients make guided choices about which risk factors
they will address, participate in realistic goal-setting
informed by national targets (table 1) [9] and then select
management option(s) for lowering risk. The relevant
patient information leaflets, described in Stage 1, support
these choices. All CHOICE patients participate in the core
module for lowering cholesterol as well as up to two
choice modules from blood pressure (BP)-lowering,
smoking cessation, increased physical activity and nutri-
tion. Patients will have the option to add additional mod-
ules on completion of the three-month program.
Additional module information will be given over the tel-
ephone and written information will be mailed to the
patient. Stage four, is telephone follow-up, consisting of
approximately four calls of around 10 minutes duration
over a three-month period, during which each patient's
risk factor(s) goals and strategies are re-evaluated and
mutually changed if necessary. CHOICE-plus patients will
receive additional telephone follow-up over 3 years as pre-
viously outlined (figure 1).
Outcome measures
The primary outcomes are TC, systolic blood pressure
(SBP), smoking rates and physical activity levels at 12 and
36 months (Table 2). Secondary outcomes include
readmission rates, all-cause mortality, cardiac mortality,
number of cardiac risk factors, waist circumference and
process measures to assess barriers to implementation and
fidelity to the intervention components (Table 2).
Self-reported physical activity will be validated in a one-
fifth subset of the cohort at 12 months by using acceler-
ometers. Accelerometry is now considered the preferred
method of objectively measuring physical activity as it
provides data that allows individual examination of
ambulatory activity frequency, intensity and duration
Table 1: Risk factor targets
Risk factor National Heart Foundation of Australia targets [9]
Smoking Complete cessation
Nutrition Establish and maintain healthy eating
Alcohol Low risk alcohol consumption
Physical activity 30 minutes of moderate activity on most days of the week
Healthy weight Waist measurement
Male ≤ 94 cm Female ≤ 80 cm
BMI 18.5–24.9 kg/m2
Lipids LDL < 2.0 mmol/l
HDL > 1.0 mmol/l
Triglycerides < 1.5 mmol/l
Blood pressure Adults ≥ 65 (unless they have diabetes and/or renal insufficiency and/or proteinuria ≥ 0.25 g/day) <140/90 mmHg
Adults <65 years; adults with diabetes and/or renal insufficiency and/or proteinuria 0.25–1.0 g/day <130/80 mmHg
Adults with proteinuria >1 g/day <125/75 mmHg
Diabetes Identify those with previously undiagnosed type 2 diabetes. In those with diabetes maintain HbA1C ≤ 7.0%BMC Cardiovascular Disorders 2008, 8:25 http://www.biomedcentral.com/1471-2261/8/25
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[23,24]. For this trial an Actigraph GT1M (formerly Com-
puter Science and Applications monitor), the most widely
accepted accelerometer in research, will be utilised [25].
The matchbox size accelerometer will be attached to a belt
that the participants in both the intervention and control
groups will be asked to wear for a period of seven consec-
utive days at one year and three years. The Active Australia
survey [26] records information from the seven-day
period immediately prior to the survey, and therefore will
be completed at the end of the week in which the acceler-
ometer is worn. Thus the accelerometry data and Active
Australia will record the same seven-day period.
To evaluate the generalisability of the previously proven
CHOICE study [21], process measures of the intervention
will include: record of participant recruitment, with-
drawal from the program, the context of the interventions
and the resources used. Barriers to implementation will be
documented. Each participant will also answer question-
naires, which will determine the dose and exposure to the
Model of CHOICE (Choice of Health Options In prevention of Cardiovascular Events) program after acute coronary syn- drome (ACS) Figure 2
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Table 2: Trial end points
Primary
TC (fasting blood sample)
SBP (resting digital reading) [27,28]
Smoking rates (self report confirmed with carbon monoxide meter) [29-31]
Physical activity (Active Australia Questionnaire validated by accelerometry) [24,26]
Secondary
Readmission rates (hospital records)
All-cause mortality (hospital records)
Cardiac mortality (hospital records)
Waist circumference (tape measurement) [32]
Number of modifiable risk factors (sum)
Process evaluation measures (including recruitment, withdrawal, barriers to participation, number and length of interventions delivered)
Tertiary
Diet (achievement of heart foundation target) [9]
Quality of life (SF12) [33]
Depression (Depression scale-short form) [34]
Angina status (Canadian Cardiovascular Society class) [35]
Modifiable risk factor knowledge (questionnaire) [19]
Cardioprotective medication use (hospital records and self-report)
Diabetic control (HbA1C)BMC Cardiovascular Disorders 2008, 8:25 http://www.biomedcentral.com/1471-2261/8/25
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elements of the program. Through this we will examine
fidelity of the program to the intervention components.
Sample size
Given the compelling evidence that lowering TC lowers
cardiovascular events, our sample size is calculated based
on change in TC. In the previous study with 70/group, we
found a 25.5 (SD 1.0) mg/dL (0.66 mmol/L) greater
reduction in TC at 12 months in the CHOICE than control
group. To demonstrate a difference between CHOICE and
CHOICE-plus groups, 138 per group in the RCT will give
80% power (2-tailed, P < 0.05) to detect a 0.35 SD effect
(13.5 mg/dl (0.35 mmol/L) difference) in TC at 12
months or 3 years. To demonstrate a difference between
the control and intervention groups at the single rand-
omized site, 64 patients will be needed in the control
group for 80% power. To allow for 20% loss to follow-up
and a design effect of up to 1.15 (ICC 0.05) due to cluster
sampling, a total of 400 patients will be recruited across
the four sites.
Statistical analysis
Primary analyses will be conducted by intention-to-treat
using SPSS for Windows (Version 12.01) and will be pre-
sented as mean and standard error of the mean or propor-
tions. Differences in outcome measures, between and
within groups, will be compared using repeated measures
ANOVAs for continuous variables and either χ2 tests or
Fishers exact tests, as appropriate, for proportions of cate-
gorical variables. Two tailed p values of < 0.05 will be con-
sidered significant. Number needed to treat will also be
calculated to estimate the number of patients who need to
receive the CHOICE intervention to lower each of the
major risk factors (TC, LDL-cholesterol, BP, smoking ces-
sation, physical activity and overweight) to below current
national targets.
Discussion
The findings of this replication study could have wide-
ranging implications for the management of patients with
CHD who are at highest risk of adverse events, namely
survivors of an ACS. We anticipate this study will demon-
strate that the large evidence-practice gap for the many
ACS survivors not accessing CR can be narrowed by a
brief, flexible and tailored modular intervention
(CHOICE) to change behavior, reduce overall cardiac risk,
and thereby reduce the likelihood of death, infarction,
and recurrent symptoms. By demonstrating the generalis-
ability of the previously proven CHOICE program, this
approach, using existing personnel and community
resources could easily be adopted state-wide at relatively
low cost.
The ultimate goal for our patients is to maintain behav-
ioural change and risk factor reduction in the long term
within their local community. At the conclusion of this
study we anticipate that we will be able to determine
whether ongoing reinforcement is important to lower
risk, and if this strategy can be implemented at multiple
sites and consequently narrow the evidence-practice gap
in the longer term.
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